We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095.
- Authors
Schouten, Jeffrey T.; Krambrink, Amy; Ribaudo, Heather J.; Kmack, Anne; Webb, Nancy; Shikuma, Cecilia; Kuritzkes, Daniel R.; Gulick, Roy M.
- Abstract
In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious.
- Subjects
DRUG side effects; DRUG efficacy; HEPATOTOXICOLOGY; THERAPEUTICS; MEDICAL experimentation on humans; QUALITATIVE research; RESEARCH methodology
- Publication
Clinical Infectious Diseases, 2010, Vol 50, Issue 5, p787
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1086/650539